Your session is about to expire
← Back to Search
GLP-1 Receptor Agonist
Exenatide for Parkinson's Disease
Phase 1
Waitlist Available
Led By David Vaillancourt, PhD
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and one-year
Awards & highlights
Study Summary
This trial will study how Exenatide affects the brain and motor skills of Parkinson's patients over time, in hopes that it will improve symptoms and slow the progression of the disease.
Eligible Conditions
- Parkinson's Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and one-year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and one-year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in blood oxygen level-dependent(BOLD) signal in M1.
Change in blood oxygen level-dependent(BOLD) signal in the posterior putamen.
Change in blood oxygen level-dependent(BOLD) signal in the supplementary motor area(SMA).
+1 moreSide effects data
From 2017 Phase 4 trial • 8 Patients • NCT0205894038%
Death
100%
80%
60%
40%
20%
0%
Study treatment Arm
Exenatide
Trial Design
1Treatment groups
Experimental Treatment
Group I: ExenatideExperimental Treatment1 Intervention
This group will receive a weekly Exenatide 2mg injection for one year.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exenatide
FDA approved
Find a Location
Who is running the clinical trial?
University of FloridaLead Sponsor
1,353 Previous Clinical Trials
713,597 Total Patients Enrolled
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,348 Previous Clinical Trials
648,056 Total Patients Enrolled
David Vaillancourt, PhDPrincipal InvestigatorUniversity of Florida
3 Previous Clinical Trials
51 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger